Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Engineering therapeutic proteins.

J McCafferty1, D R Glover

  • 1Cambridge Antibody Technology, Melbourn, Cambridgeshire, UK. john.mccafferty@cambridgeantibody.com

Current Opinion in Structural Biology
|September 12, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence and outcomes of metachronous peritoneal metastasis in the setting of obstructing colon cancer: a systematic review.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

Scientific Business Abstracts of the 113th Annual Meeting of the Association of Physicians of Great Britain and Ireland.

QJM : monthly journal of the Association of Physicians·2019
Same author

TRANSCRIPTIONAL AND PHOSPHO-PROTEOMIC SCREENS REVEAL STEM CELL ACTIVATION OF INSULIN-RESISTANCE AND TRANSFORMATION PATHWAYS FOLLOWING A SINGLE MINIMALLY TOXIC EPISODE OF ROS.

International journal of genomics and proteomics·2011
Same author

Generating a panel of highly specific antibodies to 20 human SH2 domains by phage display.

Protein engineering, design & selection : PEDS·2010
Same author

Assessing the potential of immunohistochemistry for systematic gene expression profiling.

Journal of immunological methods·2006
Same author

Human papillomavirus testing. Authors' comments.

BMJ (Clinical research ed.)·2001

Protein engineering overcomes early biotech drug limitations. Engineered antibodies and proteins show clinical benefits, improving affinity, half-life, and reducing immunogenicity for better drug candidates.

Area of Science:

  • Biotechnology
  • Protein Engineering
  • Drug Development

Background:

  • Early biotechnology-derived drug candidates often failed clinical trials.
  • Common failure reasons included low affinity/specificity, short half-lives, and immunogenicity.

Purpose of the Study:

  • To explore how protein engineering addresses challenges in drug development.
  • To highlight the clinical benefits of engineered therapeutic proteins.

Main Methods:

  • Application of protein engineering techniques.
  • Development of engineered antibodies and other proteins.

Main Results:

  • Successful circumvention of previous trial limitations.
  • Demonstrated clinical benefits from engineered protein therapeutics.

Related Experiment Videos

Conclusions:

  • Protein engineering is crucial for improving drug candidate viability.
  • Engineered antibodies and proteins offer significant therapeutic advantages.